Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
137.27B
Market cap137.27B
Price-Earnings ratio
18.95
Price-Earnings ratio18.95
Dividend yield
6.96%
Dividend yield6.96%
Average volume
49.06M
Average volume49.06M
High today
$25.11
High today$25.11
Low today
$24.06
Low today$24.06
Open price
$24.80
Open price$24.80
Volume
30.62M
Volume30.62M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$23.11
52 Week low$23.11

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $24.09. The company's market cap stands at 137.27B, with a P/E ratio of 18.95 and a dividend yield of 6.96%.

On 2026-06-24, Pfizer(PFE) stock moved within a range of $24.06 to $25.11. With shares now at $24.09, the stock is trading +0.1% above its intraday low and -4.1% below the session's peak.

Trading activity shows a volume of 30.62M, compared to an average daily volume of 49.06M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.11.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.11.

PFE News

TipRanks 46m
FDA approves Pfizer’s Ibrance combo for metastatic breast cancer

The Food and Drug Administration said it approved Pfizer’s (PFE) Ibrance in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for...

Simply Wall St 3h
Pfizer Stock And 2 AI Healthcare Picks Worth Watching

Global data is sending mixed signals on growth, inflation and interest rates, yet one trend cuts through the noise: healthcare is increasingly turning to artifi...

Pfizer Stock And 2 AI Healthcare Picks Worth Watching
Benzinga 3h
Pfizer Stock Trades Flat Following Mixed Phase 3 Lung Cancer Trial Data

Pfizer stock is showing downward bias. Where is PFE stock headed? What Are the Latest Phase 3 Results for Pfizer? Pfizer also flagged that an exploratory analys...

Pfizer Stock Trades Flat Following Mixed Phase 3 Lung Cancer Trial Data

Analyst ratings

59%

of 29 ratings
Buy
34.5%
Hold
58.6%
Sell
6.9%

More PFE News

Nasdaq 11h
Nike Names Pfizer's David Denton CFO, Succeeding Matthew Friend; Sees Q4 To Include Tariff Benefit

(RTTNews) - Athletic lifestyle footwear and apparel major NIKE, Inc. (NKE) announced late Tuesday the appointment of Pfizer, Inc.'s (PFE) David Denton as Execut...

Nike Names Pfizer's David Denton CFO, Succeeding Matthew Friend; Sees Q4 To Include Tariff Benefit
Seeking Alpha 20h
Nike taps Pfizer executive David Denton to replace Matthew Friend

Nike (NKE) announced on Tuesday that current Chief Financial Officer Matthew Friend is stepping down effective August 17 and will be replaced by Pfizer's (PFE)...

Nike taps Pfizer executive David Denton to replace Matthew Friend
The Wall Street Journal 20h
Nike Names Pfizer’s Denton as Next CFO

The new appointment comes as Nike is struggling to execute a turnaround under Chief Executive Elliott Hill, with sales dropping in the company’s key China marke...

Nike Names Pfizer’s Denton as Next CFO
24/7 Wall St. 22h
Forget Novo Nordisk. Pfizer's Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn't make the cut. Grab the names FREE today . Novo Nordisk's US...

Forget Novo Nordisk. Pfizer's Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
Benzinga 1d
Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients

While the study missed its primary overall survival endpoint in the broader patient population, it showed encouraging signals in second-line patients. SigVie-0...

Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients
Simply Wall St 1d
Pfizer Misses Main Goal For Lung Cancer Drug But Sees Subgroup Hope

Pfizer reported that its investigational cancer drug sigvotatug vedotin did not meet the primary endpoint in a pivotal Phase 3 trial in non small cell lung canc...

Pfizer Misses Main Goal For Lung Cancer Drug But Sees Subgroup Hope
24/7 Wall St. 2d
Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today . Lilly secured f...

Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.